2024
IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination
Park H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, Jeon S, You S, Racke M, Bucala R, Kang I. IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination. EBioMedicine 2024, 103: 105114. PMID: 38640835, PMCID: PMC11041015, DOI: 10.1016/j.ebiom.2024.105114.Peer-Reviewed Original ResearchConceptsCD4<sup>+</sup> T cellsCOVID-19 mRNA vaccinesAntigen-specific CD4<sup>+</sup> T cell responsesT cell responsesPrimary antibody deficiencyCD4<sup>+</sup> T cell responsesT cellsIL-1R1MRNA vaccinesIL-1IgG antibodiesAntigen-specific CD4<sup>+</sup> T cellsCD4+ T cell responsesLevels of IL-1R1Human CD4<sup>+</sup> T cellsIL-1 receptor 1Healthy individualsDose of COVID-19 mRNA vaccineAntigen-specific CD4IL-1R1 expressionT cell immunityRepetitive antigenic stimulationCytokines interleukin (IL)-1Immune response to virusesExpression of IL-1R1Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines
Adin M, Isufi E, Wu J, Pang Y, Nguyen D, Has D, Caner C, Aboueldaha N, Mossa-Basha M, Pucar D. Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines. Nuclear Medicine Communications 2024, 45: 474-480. PMID: 38465449, DOI: 10.1097/mnm.0000000000001833.Peer-Reviewed Original ResearchAxillary lymph nodesWhole virus vaccineLymph nodesMRNA vaccinesNatural courseValue of clinical parametersCOVID-19 mRNA vaccinesPredictive value of clinical parametersDose of vaccine administrationPET-CT studiesCohort of oncology patientsDeauville criteriaPET criteriaClinical parametersYounger patientsSingle doseModerna recipientsJ&J vaccinePET-positiveMultivariate analysisVaccine typesOncology patientsPredictive valueVaccine administrationModerna vaccine
2023
2368. SARS-CoV-2 mRNA vaccination induces B cell immunity in the tonsils and adenoids of children
Xu Q, Mudd P, Behzadpour H, Bellusci L, Grubbs G, Pourhashemi S, Tang J, Liu C, Newman D, Shi L, Milanez-Almeida P, Kardava L, Tsang J, Moir S, Khurana S, Schwartzberg P, Manthiram K. 2368. SARS-CoV-2 mRNA vaccination induces B cell immunity in the tonsils and adenoids of children. Open Forum Infectious Diseases 2023, 10: ofad500.1989. PMCID: PMC10677082, DOI: 10.1093/ofid/ofad500.1989.Peer-Reviewed Original ResearchSARS-CoV-2-specific B cellsMemory B cellsB cellsAdenoids of childrenMRNA vaccinesVaccinated subjectsPeripheral bloodInfected subjectsUpper respiratory tract lymphoid tissueSARS-CoV-2IgA+ memory B cellsSARS-CoV-2 mRNA vaccinesGerminal center B cellsRobust adaptive immune responsesPost-vaccinationCOVID-19 mRNA vaccinesB-cell phenotypeB cell immunityAdaptive immune responsesImmunity to SARS-CoV-2SARS-CoV-2 infectionPost-infectionLymphoid tissueAdenoidsMucosal IgACOVID‐19 mRNA vaccine, but not a viral vector‐based vaccine, promotes neutralizing anti‐type I interferon autoantibody production in a small group of healthy individuals
Xu W, Wen X, Cong X, Jiang W. COVID‐19 mRNA vaccine, but not a viral vector‐based vaccine, promotes neutralizing anti‐type I interferon autoantibody production in a small group of healthy individuals. Journal Of Medical Virology 2023, 95: e29137. PMID: 37792386, PMCID: PMC10603818, DOI: 10.1002/jmv.29137.Peer-Reviewed Original ResearchConceptsViral vector-based vaccinesCOVID-19 mRNA vaccinesVector-based vaccinesGroup of healthy individualsMRNA vaccinesHealthy individualsPlasma levelsAnti-type I IFN autoantibodiesI interferonLevels of IgG autoantibodiesEvaluate plasma levelsHuman self-antigensPost-COVID-19 vaccinationCOVID-19 vaccineImpaired immune defenseInduce adverse eventsBaseline in vitroIncreased antibody levelsSARS-CoV-2 infectionSARS-CoV-2 antigensType I IFNType I interferonAutoantibody productionSelf-antigensInduce autoimmunityModulating IL-1β and its receptors shapes spike-specific CD4+ T cell responses to mRNA vaccination
Park H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, You S, Racke M, Bucala R, Kang I. Modulating IL-1β and its receptors shapes spike-specific CD4+ T cell responses to mRNA vaccination. The Journal Of Immunology 2023, 210: 159.20-159.20. DOI: 10.4049/jimmunol.210.supp.159.20.Peer-Reviewed Original ResearchCOVID-19 mRNA vaccinesT cellsIL-1βIL-1R2MRNA vaccinesIL-1 receptor 1IL-1R1 expressionIL-1R2 expressionSpike-specific CD4Vaccine-induced CD4T cell immunityT cell responsesSpecific antibody productionMRNA vaccinationCell immunityDurable immunityIL-1R1IL-1BCD4Healthy individualsQuest DiagnosticsAntibody productionCell responsesReceptor 1Receptor systemRevaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C, Thomsen M, Andersen J, Jensen J, Bayarri-Olmos R, Garred P, Hermansen M, Johannsen A, Larsen M, Mistegaard C, Mikkelsen S, Nielsen L, Olesen R, Pérez-Alós L, Vils S, Szabados F, Søgaard O, Tolstrup M, Erikstrup C, Hauge E, Troldborg A. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients. Clinical And Experimental Rheumatology 2023, 42: 157-165. PMID: 37877429, DOI: 10.55563/clinexprheumatol/orpp04.Peer-Reviewed Original ResearchT cell responsesDetectable antibody responseBlood donorsSARS-CoV-2Antibody responseB cellsRheumatic diseasesCOVID-19 vaccine responsesSARS-CoV-2 antibodiesCOVID-19 mRNA vaccinesRevaccination of patientsSystemic lupus erythematosusB cell levelsCOVID-19 vaccinationPercent of casesDetectable serological responsesSARS-CoV-2 spike proteinAntibody class switchRD cohortLupus erythematosusVaccine responsesAntibody levelsRheumatoid arthritisSpecific IgGMRNA vaccinesClinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients
Li J, Lee M, Peng S, Bin Lee A, Tay R, Chee C, Ho C, Walsh J, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients. European Journal Of Surgical Oncology 2023, 49: e60-e61. PMCID: PMC9941290, DOI: 10.1016/j.ejso.2022.11.202.Peer-Reviewed Original Research
2022
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
John BV, Ferreira RD, Doshi A, Kaplan DE, Taddei TH, Spector SA, Paulus E, Deng Y, Bastaich D, Dahman B. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal Of Hepatology 2022, 77: 1349-1358. PMID: 36181987, PMCID: PMC9519143, DOI: 10.1016/j.jhep.2022.07.036.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesCritical COVID-19COVID-19-related deathsThird doseMRNA vaccinesCOVID-19Propensity-matched control groupRetrospective cohort studyModerate COVID-19Symptomatic COVID-19Veterans Health AdministrationBNT-162b2BNT162b2 mRNAModerna mRNACohort studyImmune dysregulationCirrhosisSimilar riskGeneral populationMagnitude of reductionPatientsControl groupHealth AdministrationVaccineAbstractTextDefining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Shin JJ, Par-Young J, Unlu S, McNamara A, Park HJ, Shin MS, Gee RJ, Doyle H, Afinogenova Y, Zidan E, Kwah J, Russo A, Mamula M, Hsu FI, Catanzaro J, Racke M, Bucala R, Wilen C, Kang I. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. Journal Of Clinical Immunology 2022, 42: 1137-1150. PMID: 35713752, PMCID: PMC9203263, DOI: 10.1007/s10875-022-01296-4.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCD8-Positive T-LymphocytesCommon Variable ImmunodeficiencyCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunoglobulin AImmunoglobulin GmRNA VaccinesPrimary Immunodeficiency DiseasesRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccinesVaccines, SyntheticConceptsCommon variable immune deficiencyT cellsImmune responseIgG responsesCVID patientsMRNA vaccinesB cellsCoronavirus disease 2019 (COVID-19) mRNA vaccinesCOVID-19 mRNA vaccinesBaseline immune profileHistory of autoimmunityPrimary antibody deficiencyT cell responsesCellular immune responsesPoor immune responseVariable immune deficiencyMemory B cellsSARS-CoV-2 spike proteinBaseline IgGCVID diagnosisEM CD8Immunological predictorsPAD cohortSpecific CD4Immune profileMyocarditis after COVID‐19 mRNA vaccination: A systematic review of case reports and case series
Park D, An S, Kaur A, Malhotra S, Vij A. Myocarditis after COVID‐19 mRNA vaccination: A systematic review of case reports and case series. Clinical Cardiology 2022, 45: 691-700. PMID: 35652390, PMCID: PMC9286338, DOI: 10.1002/clc.23828.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine-associated myocarditisVaccine-associated myocarditisCOVID-19 mRNA vaccinesMRNA vaccinesSystematic review of case reportsCOVID-19 vaccineReview of case reportsAverage time to onsetElevation of troponinNonsteroidal anti-inflammatory drugsCases of myocarditisDisease severity of COVID-19Time to onsetLength of hospitalizationOccurrence of myocarditisDose of COVID vaccineAnti-inflammatory drugsPain 3Severity of COVID-19Anti-COVID-19 vaccineSystematic literature searchChest painFavorable prognosisCase seriesClinical characteristicsEfficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M, Tay S, Teo C, Tan B, Chan Y, Sundar R, Soon Y. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. The BMJ 2022, 376: e068632. PMID: 35236664, PMCID: PMC8889026, DOI: 10.1136/bmj-2021-068632.Peer-Reviewed Original ResearchConceptsImmune mediated inflammatory disorderOrgan transplant recipientsEfficacy of COVID-19 vaccinesTransplant recipientsRisk of biasImmunocompromised patientsSolid cancersInflammatory disordersImmunocompetent controlsHaematological cancersSeroconversion ratesMeta-analysisCOVID-19 vaccineMRNA vaccinesVaccine doseSystematic reviewCOVID-19 mRNA vaccinesWHO International Clinical Trials Registry PlatformCentral Register of Controlled TrialsVaccine non-respondersAssociated with seroconversionInternational Clinical Trials Registry PlatformProspective observational studyRegister of Controlled TrialsLow risk of bias
2021
572. Real-world Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in a Retrospective Cohort
Vahidy F, Pischel L, Tano M, Pan A, Boom M, Sostman H, Nasir K, Omer S. 572. Real-world Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in a Retrospective Cohort. Open Forum Infectious Diseases 2021, 8: 388-388. PMCID: PMC8644874, DOI: 10.1093/ofid/ofab466.770.Peer-Reviewed Original ResearchCOVID-19 mRNA vaccinesVaccine effectivenessImmunization statusMRNA vaccinesDose groupRetrospective cohortSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinesSARS-CoV-2 mRNA vaccinesCOVID-19 related hospitalizationsCox proportional hazards modelDiverse US cohortCharlson Comorbidity IndexReal-world effectivenessProportional hazards modelCOVID-19 hospitalizationCOVID-19 mortalityArea Deprivation IndexHealth care systemMore comorbiditiesComorbidity indexRelated hospitalizationsCohort enrollmentUS cohortClinical trialsOdds ratioAssociation of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis
John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine 2021, 181: 1306-1314. PMID: 34254978, PMCID: PMC8278308, DOI: 10.1001/jamainternmed.2021.4325.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19-related hospitalizationBNT162b2 mRNAFirst doseCohort studySecond doseMRNA vaccinesClinical trialsControl groupPropensity-matched control groupPhase 3 clinical trialsCOVID-19 mRNA vaccinesAssociation of vaccinationRetrospective cohort studyUS veteran populationAssociation of receiptVeterans Health AdministrationCoronavirus disease 2019COVID-19 hospitalizationMRNA vaccine administrationCOVID-19Vaccine recipientsImmune dysregulationModerna mRNAMedian ageImmunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
Wisnewski AV, Redlich CA, Liu J, Kamath K, Abad QA, Smith RF, Fazen L, Santiago R, Luna J, Martinez B, Baum-Jones E, Waitz R, Haynes WA, Shon JC. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0252849. PMID: 34499652, PMCID: PMC8428655, DOI: 10.1371/journal.pone.0252849.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccine recipientsLinear epitopesSARS-CoV-2 neutralizationCOVID-19 mRNA vaccinesVaccine-induced IgGMRNA vaccine recipientsSARS-CoV-2 spike proteinDominant linear epitopeElicit IgGVaccine recipientsVaccine effectivenessMRNA vaccinesVaccination samplesImmune escapeHuman coronavirusesHealthy adultsSARS-CoVVaccine epitopesCritical epitopesAdverse responsesReverse vaccinologySpike proteinNatural infectionS2 subunitIgGAssociation of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging
Adin ME, Isufi E, Kulon M, Pucar D. Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging. JAMA Oncology 2021, 7: 1241-1242. PMID: 34110378, PMCID: PMC8193545, DOI: 10.1001/jamaoncol.2021.1794.Peer-Reviewed Original ResearchMyopericarditis in young adults presenting to the emergency department after receiving a second COVID‐19 mRNA vaccine
Fleming‐Nouri A, Haimovich AD, Yang D, Schulz WL, Coppi A, Taylor RA. Myopericarditis in young adults presenting to the emergency department after receiving a second COVID‐19 mRNA vaccine. Academic Emergency Medicine 2021, 28: 802-805. PMID: 34310793, PMCID: PMC8441914, DOI: 10.1111/acem.14307.Peer-Reviewed Original ResearchHuman IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski AV, Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0249499. PMID: 34133415, PMCID: PMC8208542, DOI: 10.1371/journal.pone.0249499.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesAntigen-specific IgGMRNA vaccinesIgG levelsCOVID-19 mRNA vaccinationAntigen-specific IgG levelsInitial vaccine doseAntigen-specific IgASARS-CoV-2More rapid declineSecond vaccineVaccine doseMRNA vaccinationIgA responsesSerum levelsVaccine dosesSpecific IgGNatural immunityViral neutralizationIgAVaccinePeak levelsIgGVaccinationHuman IgG
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply